# US 6,730,681 B2 · Triazolo-pyrimidine derivatives as ligands for gaba receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,681 B2
- Document ID: US6730681B2
- Status: Granted
- Kind: B2
- Application number: 10/149,851
- Filed: 2002-06-14
- Published: 2003-03-06
- Granted: 2004-05-04
- Earliest claimed: 1999-12-15
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Mark Stuart Chambers; Ian James Collins; Simon Charles Goodacre; David James Hallett; Philip Jones; Linda Elizabeth Keown; Robert James Maxey; Leslie Joseph Street
- Web page: https://patentgrep.com/patent/US6730681B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/22: Anxiolytics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A class of substituted or 6,7-ring fused [1, 2, 3]triazolo[1,5-α]-pyrimidine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and an amino moiety at the 5-position, are selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.

## Claims

### Claim 1

A compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein:
Y represents hydrogen or C1-6 alkyl; and
Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C6-8 bicycloalkyl, phenyl, naphthyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazepanyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, C2-7 alkoxycarbonyl or di(C1-6)alkylamino, which groups are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7, cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6alkylamino(C1-6alkyl, di(C1-6)alkylamino-carbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl; or
Y and Z are taken together with the two intervening carbon atoms to form a ring selected from C5-9 cycloalkenyl, C6-10 bicycloalkenyl, tetrahydropyridinyl, pyridinyl and phenyl, any of which rings may be benzo-fused, or unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylamino-carbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl;
R1 represents C3-7 cycloalkyl, phenyl, furyl, thienyl or pyridinyl, which groups may be unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl;
R2 represents hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl or C1-6 alkoxy(C1-6)alkyl; and
R3 represents C1-6 alkyl, C3-7 cycloalkyl(C1-6)alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazepanyl, furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, oxazolylmethyl, oxazolylethyl, isoxazolylmethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, benzimidazolylmethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyridazinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl, isoquinolinylmethyl or quinoxalinylmethyl, any of which groups are unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alky and imidazolyl(C1-6)alkyl;
R2 and R3 are taken together with the intervening nitrogen atom to form a ring of formula (a), (b), (c), (d), (e), (f), (g), (h), (j) or (k):
wherein:
X represents oxygen, sulphur, N—R5 or CR6R7;
R4 represents hydrogen, C1-6 alkyl, phenyl, naphthyl, C2-7 alkoxycarbonyl, phenyl(C1-6)alkoxy(C1-6)alkyl or naphthyl(C1-6)alkoxy(C1-6)alkyl;
R5 represents hydrogen, C1-6 alkyl, di(C1-6)alkylamino(C1-6)alkyl, C2-6 alkenyl, C3-7 cycloalkyl(C1-6)alkyl, phenyl, naphthyl, azetidinyl(C1-6)alkyl, pyrrolidinyl(C1-6)alkyl, piperidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, thiomorpholiny(C1-6)alkyl, diazepanyl(C1-6)alkyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, C2-7 alkylcarbonyl or C2-7 alkoxycarbonyl;
R6 represents hydrogen, halogen, hydroxy, C1-6 alkoxy, di(C1-6)alkylamino, C2-7 alkoxycarbonyl, a azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, or diazepanyl group which may be phenyl fused and which is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl; and
R7 represents hydrogen, C1-6 alkyl, or phenyl, naphthyl, phenyl(C1-6)alkyl or naphthyl(C1-6)alkyl group which is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 of formula IIA, or a pharmaceutically acceptable salt thereof:
wherein:
R18 represents hydrogen or halogen; and
Q represents the residue of a ring of formula (a), (b), (c), (d), (e), (f), (g), (h), (j) or (k) as defined in claim 1.

### Claim 3 (depends on 1)

The compound of claim 1 of formula IIB, or a pharmaceutically acceptable salt thereof:
wherein:
R18 represents hydrogen or halogen;
n is 1 or 2; and
R13 represents hydroxy or C1-6 alkoxy, or a phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl or tetrazolyl group, which group is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylamino-carbonyl(C1-6alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl.

### Claim 4 (depends on 3)

The compound of claim 3 of formula IIC, or a pharmaceutically acceptable salt thereof:
wherein:
R23 represents hydrogen, methyl or ethyl.

### Claim 5 (depends on 1)

The compound of claim 1 formula IID, or a pharmaceutically acceptable salt thereof:
wherein:
Q represents the residue of a ring of formula (a), (b), (c), (d), (e), (f), (g), (h), (j) or (k) as defined in claim 1; and
Z1 represents C1-6 alkyl, C3-7 cycloalkyl or phenyl, naphthyl group, which group is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl.

### Claim 6 (depends on 1)

The compound of claim 1 of the formula IIE, and salts thereof:
wherein:
n is 1 or 2;
R13 represents hydroxy or C1-6 alkoxy, or a phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl group, which group is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl; and
Z1 represents C1-6 alkyl, C3-7 cycloalkyl, phenyl or naphthyl group, which group is unsubstituted or substituted with one or more substituents selected from: C1-6alkyl, phenyl(C1-6)alkyl, naphthyl(C1-6)alkyl, pyridyl(C1-6)alkyl, halogen, halo(C1-6)alkyl, cyano, cyano(C1-6)alkyl, hydroxy, hydroxymethyl, C1-6alkoxy, C3-7 cycloalkyl(C1-6)alkoxy, C3-7 cycloalkoxy, amino(C1-6)alkyl, di(C1-6)alkylamino(C1-6)alkyl, di(C1-6)alkylaminocarbonyl(C1-6)alkyl, N-(C1-6)alkylpiperidinyl, pyrrolidinyl(C1-6)alkyl, piperazinyl(C1-6)alkyl, morpholinyl(C1-6)alkyl, di(C1-6)alkylmorpholinyl(C1-6)alkyl and imidazolyl(C1-6)alkyl.

### Claim 7 (depends on 6)

The compound of claim 6 represented by formula IIF, and salts thereof:
wherein:
R23 represents hydrogen, methyl or ethyl.

### Claim 8 (depends on 1)

The compound of claim 1 which is selected from the group consisting of:
3-(2-fluorophenyl)-5-(morpholin-4-yl)-[1 ,2,3]triazolo[1,5-α]quinazoline;
5-[5,6-dihydroimidazo]1,2-α]pyrazin-7(8H)-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-5,6-dihydroimidazo]1,5-α]pyrazin-7(8H)-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-[5,6-dihydro[1,2,4]triazolo[1,5-α]pyrazin-7(8H)-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(3-oxo-4-phenylpiperazin-1-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-(4-ethoxycarbonylpiperazin-1-yl)-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-(3-ethoxycarbonylpiperidin-1-yl)-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-(4-ethoxycarbonylpiperidin-1-yl)-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(4-hydroxypiperidin-1-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[4-(pyridin-4-yl)piperazin-1-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[4-(pyridin-2-yl)piperazin-1-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
5-(4-acetylpiperazin-1-yl)-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[2-oxopiperazin-4(1H)-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(1-methyl-2-oxopiperazin-4-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-[5,6-dihydroimidazo[1,2-α]pyrazin-7(8H)-yl]-7-fluoro-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-[bis(2-methoxyethyl)amino]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(thiomorpholin-4-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-[4-(dimethylamino)piperidin-1-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[4-(pyrrolidin-1-yl)piperidin-1-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[4-(piperidin-1-yl)piperidin-1-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
5-[bis(2-hydroxyethyl)amino]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(4-oxopiperidin-1-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
5-(1-ethyl-2-oxopiperazin-4-yl)-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(2-oxo-1-propylpiperazin-4-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-[2-oxo-1-(2-propenyl)piperazin-4-yl]-[1,2,3]triazolo-[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(4-hydroxy-4-methylpiperidin-1-yl)-[1,2,3]triazolo-[1,5-α]quinazoline;
1-{4-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]piperazin-1-yl)}propan-1-one;
2,2-dimethyl-1-{4-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]piperazin-1-yl}propan-1-one; and salts thereof.

### Claim 9 (depends on 1)

The compound of claim 1 which is selected from the group consisting of:
N-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]-N-methyl-N-(1-methylpiperidin-4-yl)amine;
1-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]-[1,4]diazepan-5-one;
3-(2-fluorophenyl)-5-(piperidin-1-yl)-[1,2,3]triazolo[1,5-α]quinazolin;
3-(2-fluorophenyl)-5-[4-(morpholin-4-yl)piperidin-1-yl]-[1,2,3]triazolo[1,5-α]quinazoline;
4-(2-dimethylaminoethyl)-1-[3-(2-Fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]-1,4]diazepan-5-one;
1′-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]-[1,4′]bipiperidinyl-4-carboxylic acid ethyl ester;
5-[4-(3,4-dihydro-1H-isoquinolin-2-yl)piperidin-1-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazoline;
1-{1-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]piperidin-4-yl}-[1,4]diazepan-5-one;
N,N-dimethyl-N-{1-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]pyrrolidin-3-yl}amine;
3-(2-fluorophenyl)-5-{4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-[1,2,3]triazolo[1,5-α]quinazoline;
3-(2-fluorophenyl)-5-(4-methoxypiperidin-1-yl)-[1,2,3]triazolo[1,5-α]quinazoline;
1-cyclopropylmethyl-4-[3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-α]quinazolin-5-yl]piperazin-2-one;
and salts thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

A method for the treatment of anxiety which comprises administering to a patient in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A method for the prevention of anxiety which comprises administering to a patient in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
